Private equity firm True North-backed Bangalore-based Anthem Biosciences, a contract research, development and manufacturing organisation, is set to launch its Rs 3,395-crore initial public offering for subscription in the coming week on July 14.

The public issue will remain open till July 16. The anchor book will be launched for institutional investors on July 11.

The company will finalise IPO share allotment by the end of July 17, and Anthem Biosciences shares will be available for trading on the bourses effective July 21.

The IPO comprises of solely offer-for-sale by existing shareholders including promoters.

Promoters Ganesh Sambasivam, and K Ravindra Chandrappa will be selling Rs 350 crore worth shares each, while Indian private equity group True North-owned Viridity Tone LLP (which holds 7.93 percent shares in the company) will be the largest selling shareholder amongst the sellers, offloading Rs 1,325 crore worth shares.


Investor Portsmouth Technologies, and other selling shareholders - Malay J Barua, Rupesh N Kinekar, and Satish Sharma will be selling shares worth RS 320 crore each.

The company has formed a strategic partnership with DavosPharma (an affiliate of Portsmouth LLC, the shareholder in the company with 3.74 percent stake), the sales partner in the United States. As a result, it has onboarded 89 customers in United States including 83 emerging biotech customers over the last three fiscals.

As of March 2025, it had more than 550 customers across both CRDMO and specialty ingredients businesses in more than 44 countries including the United States, European countries and Japan. Its top 5 customers contributed 70.92 percent to the revenue in fiscal 2025.

Anthem Biosciences has three manufacturing facilities - Unit I in Bommassandra, Unit II in Harohalli and Unit III in Harohalli. Amongst them, Unit III in Harohalli is under construction and is expected to be completed by the first half of FY26.

Its manufacturing facilities are cGMP compliant and have been accredited by various global regulatory agencies, such as the FDA in the United States, ANVISA in Brazil, TGA in Australia and PMDA in Japan.

On the financial front, Anthem Biosciences has recorded net profit at Rs 451.3 crore for the year ended March 2025, growing 22.9 percent over Rs 367.3 crore in the previous fiscal. Revenue during the same period increased by 30 percent to Rs 1,844.6 crore, up from Rs 1,419.4 crore.

The book running lead managers handling the Anthem Biosciences IPO are JM Financial, Citigroup Global Markets India, JP Morgan India, and Nomura Financial Advisory and Securities (India).